Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Rating) have been assigned an average rating of “Buy” from the seven brokerages that are currently covering the company, MarketBeat reports. One analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $46.17.
Separately, Zacks Investment Research cut shares of Pliant Therapeutics from a “hold” rating to a “sell” rating in a report on Friday, March 4th.
A number of hedge funds have recently made changes to their positions in PLRX. CHI Advisors LLC boosted its stake in Pliant Therapeutics by 4.9% in the third quarter. CHI Advisors LLC now owns 2,484,724 shares of the company’s stock valued at $41,942,000 after acquiring an additional 116,836 shares during the last quarter. BlackRock Inc. lifted its stake in Pliant Therapeutics by 8.8% in the fourth quarter. BlackRock Inc. now owns 1,687,874 shares of the company’s stock valued at $22,785,000 after purchasing an additional 135,882 shares during the last quarter. Citadel Advisors LLC grew its holdings in Pliant Therapeutics by 1.8% during the fourth quarter. Citadel Advisors LLC now owns 1,337,126 shares of the company’s stock valued at $18,051,000 after purchasing an additional 23,560 shares during the period. Point72 Asset Management L.P. bought a new position in Pliant Therapeutics during the fourth quarter valued at $15,324,000. Finally, State Street Corp increased its position in Pliant Therapeutics by 6.4% in the fourth quarter. State Street Corp now owns 444,629 shares of the company’s stock worth $6,002,000 after buying an additional 26,626 shares during the last quarter. 84.38% of the stock is currently owned by institutional investors and hedge funds.
Pliant Therapeutics Company Profile (Get Rating)
Pliant Therapeutics, Inc, a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials.
- Get a free copy of the StockNews.com research report on Pliant Therapeutics (PLRX)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.